BlackRock
TRDA icon

BlackRock’s Entrada Therapeutics TRDA Stock Holding History

BlackRock’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Buy
2,583,333
+224,540
+10% +$2.15M ﹤0.01% 3292
2026
Q1 		$29.8M Buy
2,358,793
+211,533
+10% +$2.42M ﹤0.01% 2829
2025
Q4 		$22.1M Buy
2,147,260
+103,216
+5% +$870K ﹤0.01% 3046
2025
Q3 		$11.9M Buy
2,044,044
+21,894
+1% +$128K ﹤0.01% 3365
2025
Q2 		$13.6M Buy
2,022,150
+31,297
+2% +$252K ﹤0.01% 3243
2025
Q1 		$18M Buy
1,990,853
+16,401
+0.8% +$204K ﹤0.01% 2999
2024
Q4 		$34.1M Buy
1,974,452
+151,617
+8% +$2.75M ﹤0.01% 2701
2024
Q3 		$29.1M Buy
1,822,835
+128,968
+8% +$2.03M ﹤0.01% 2801
2024
Q2 		$24.1M Buy
1,693,867
+207,699
+14% +$2.95M ﹤0.01% 2858
2024
Q1 		$21.1M Sell
1,486,168
-16,369
-1% -$231K ﹤0.01% 2965
2023
Q4 		$22.7M Buy
1,502,537
+98,134
+7% +$1.45M ﹤0.01% 2944
2023
Q3 		$22.2M Sell
1,404,403
-1,403
-0.1% -$22.1K ﹤0.01% 2886
2023
Q2 		$21.3M Buy
1,405,806
+1,193,821
+563% +$16.4M ﹤0.01% 3007
2023
Q1 		$3.07M Buy
211,985
+23,991
+13% +$320K ﹤0.01% 3855
2022
Q4 		$2.54M Buy
187,994
+40,401
+27% +$708K ﹤0.01% 4030
2022
Q3 		$2.33M Buy
147,593
+82,594
+127% +$1.05M ﹤0.01% 4112
2022
Q2 		$791K Sell
64,999
-380,521
-85% -$2.89M ﹤0.01% 4627
2022
Q1 		$4.18M Buy
445,520
+1,094
+0.2% +$11.7K ﹤0.01% 4057
2021
Q4 		$7.61M Buy
+444,426
New +$10.8M ﹤0.01% 3814

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's TRDA Position: Q2 2026 in Review

BlackRock increased its Entrada Therapeutics (TRDA) stake by 9.5% in Q2 2026, buying an estimated $2.15M and bringing the position to 2,583,333 shares worth $19M. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

BlackRock first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $34.1M in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • BlackRock held 2,583,333 shares of Entrada Therapeutics worth $19M as of Q2 2026.
  • BlackRock bought 224,540 Entrada Therapeutics shares in Q2 2026, an estimated $2.15M.
  • Entrada Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3292 holding.
  • BlackRock first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • BlackRock's Entrada Therapeutics position peaked at $34.1M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.